CY1120646T1 - Προγονικα κυτταρα μεσοδερμικης προελευσης - Google Patents

Προγονικα κυτταρα μεσοδερμικης προελευσης

Info

Publication number
CY1120646T1
CY1120646T1 CY181100736T CY181100736T CY1120646T1 CY 1120646 T1 CY1120646 T1 CY 1120646T1 CY 181100736 T CY181100736 T CY 181100736T CY 181100736 T CY181100736 T CY 181100736T CY 1120646 T1 CY1120646 T1 CY 1120646T1
Authority
CY
Cyprus
Prior art keywords
origin
intermederal
original cells
cells
original
Prior art date
Application number
CY181100736T
Other languages
English (en)
Inventor
Thomas Averell Houze
Martin John Evans
Ajan Reginald
Ina Laura Pieper
Brian Lee Perkins
Original Assignee
Cell Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1111500.3A external-priority patent/GB201111500D0/en
Priority claimed from GBGB1111505.2A external-priority patent/GB201111505D0/en
Priority claimed from GBGB1111503.7A external-priority patent/GB201111503D0/en
Priority claimed from GBGB1111509.4A external-priority patent/GB201111509D0/en
Application filed by Cell Therapy Ltd filed Critical Cell Therapy Ltd
Publication of CY1120646T1 publication Critical patent/CY1120646T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)

Abstract

Η εφεύρεση αφορά προγονικά κύτταρα μεσοδερμικής προέλευσης και τη θεραπευτική χρήση τους.
CY181100736T 2011-07-06 2018-07-16 Προγονικα κυτταρα μεσοδερμικης προελευσης CY1120646T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1111500.3A GB201111500D0 (en) 2011-07-06 2011-07-06 Wet age-related macular degeneration MSC subtype
GBGB1111505.2A GB201111505D0 (en) 2011-07-06 2011-07-06 MI MSC subtype
GBGB1111503.7A GB201111503D0 (en) 2011-07-06 2011-07-06 Heart failure (HF) MSC subtype
GBGB1111509.4A GB201111509D0 (en) 2011-07-06 2011-07-06 Orthopedic MSC subtype
PCT/GB2012/051600 WO2013005053A2 (en) 2011-07-06 2012-07-06 Progenitor cells of mesodermal lineage

Publications (1)

Publication Number Publication Date
CY1120646T1 true CY1120646T1 (el) 2019-12-11

Family

ID=46513785

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100736T CY1120646T1 (el) 2011-07-06 2018-07-16 Προγονικα κυτταρα μεσοδερμικης προελευσης

Country Status (19)

Country Link
US (3) US10472609B2 (el)
EP (1) EP2729562B1 (el)
JP (2) JP6607675B2 (el)
CN (2) CN104508124B (el)
AU (2) AU2012279995C1 (el)
CA (1) CA2840307C (el)
CY (1) CY1120646T1 (el)
DK (1) DK2729562T3 (el)
EA (1) EA029577B1 (el)
ES (1) ES2675693T3 (el)
HR (1) HRP20181152T1 (el)
HU (1) HUE039236T2 (el)
IL (2) IL230071B (el)
LT (1) LT2729562T (el)
MY (1) MY185016A (el)
PL (1) PL2729562T3 (el)
PT (1) PT2729562T (el)
SG (1) SG10201605518XA (el)
WO (1) WO2013005053A2 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335195A1 (en) 2011-11-23 2014-11-13 Cell Therapy Limited Platelet lysate gel
AU2014331523B2 (en) * 2013-10-04 2020-10-01 Cell Ideas Pty Ltd Biomarkers for cell therapy
GB201408712D0 (en) * 2014-05-16 2014-07-02 Univ Leuven Kath Mesodermal progenitor cells
GB201410504D0 (en) 2014-06-12 2014-07-30 Cell Therapy Ltd Immuno-modulaltory progenitor (IMP) cell
RU2017109584A (ru) * 2014-08-29 2018-10-01 Бектон, Дикинсон Энд Компани Способы и композиции для получения оценки туберкулеза у субъекта
WO2016131430A1 (en) * 2015-02-20 2016-08-25 Shih-Chieh Hung Use of mesenchymal stem cells in treating osteoarthritis
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
GB201513996D0 (en) * 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
JP6830893B2 (ja) * 2015-09-11 2021-02-17 アステラス製薬株式会社 腎前駆細胞を製造する方法
GB201518263D0 (en) 2015-10-15 2015-12-02 Oxford Bioelectronics Ltd Method
CN105483206B (zh) * 2016-01-06 2019-09-13 北京汉氏联合生物技术股份有限公司 一种用vcam-1检测msc促内皮细胞增殖能力的方法
KR20190039822A (ko) * 2016-08-29 2019-04-15 해컨색 유니버시티 메디컬 센터 인간에서 혈소판-유사 세포를 함유하는 혈액의 혈소판 풍부 분획의 줄기세포능을 통해 성체 세포를 재프로그래밍하기 위한 조성물 및 방법
AU2017321300B2 (en) * 2016-08-29 2022-11-17 Hackensack University Medical Center Compositions and methods for programming adult cells with platelet rich fraction of blood containing platelet-like cells
JP7009977B2 (ja) * 2017-12-25 2022-01-26 国立大学法人東海国立大学機構 被検体の血中ｖｅｇｆ－ａに関する測定値を用いた心疾患の重症度及び予後予測を行うための方法、装置及びコンピュータプログラム
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
CN108715833B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
JP7416786B2 (ja) * 2018-11-14 2024-01-17 オンデルゾークス・エン オントビッケリングスフォンズ オーデ クラウス・フランデレン 血小板放出物を調製するための方法
CN109329270A (zh) * 2018-11-19 2019-02-15 成都清科生物科技有限公司 一种静脉回输用间充质干细胞保存液及其制备方法
GB201900554D0 (en) 2019-01-15 2019-03-06 Cell Therapy Ltd Mesodermal killer (mk) cell
AU2020209441A1 (en) * 2019-01-15 2021-08-12 Cell Therapy Limited Mesodermal killer (MK) cell
WO2020157660A1 (en) * 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
WO2020231968A1 (en) * 2019-05-15 2020-11-19 Stemcyte Inc. High concentration cell packaging and shipping
CN110237094B (zh) * 2019-07-30 2023-10-03 天晴干细胞股份有限公司 一种底层血小板因子贴及sPL血小板因子凝胶贴膜的制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
RU2138162C1 (ru) 1997-04-17 1999-09-27 Суханов Владимир Александрович Способ криоконсервации богатой тромбоцитами плазмы
WO1999001145A1 (en) 1997-07-03 1999-01-14 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
WO1999011287A1 (en) 1997-09-04 1999-03-11 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
WO1999061587A1 (en) 1998-05-29 1999-12-02 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
NZ517002A (en) 1999-08-05 2004-06-25 Mcl Llc Multipotent adult stem cells and methods for isolation
AUPR703601A0 (en) 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
JP2003055237A (ja) * 2001-08-15 2003-02-26 Japan Science & Technology Corp 骨再生促進剤
JP2005517441A (ja) 2002-02-19 2005-06-16 メディポスト・カンパニー・リミテッド 臍帯血由来の間葉幹細胞・前駆細胞の分離培養方法及び間葉組織への分化誘導方法
KR100534215B1 (ko) 2003-11-11 2005-12-08 (주)히스토스템 냉동 보관된 제대혈로부터 중간엽 줄기세포의 분리 및 배양 방법
DE102005011571A1 (de) 2004-04-13 2005-11-17 Man Roland Druckmaschinen Ag Prägeeinrichtung für Wellpappe in einer Bogendruckmaschine
DE602005025772D1 (de) 2004-07-20 2011-02-17 Univ Case Western Reserve Neue zellpopulationen und deren anwendungen
EP2361970A1 (en) 2004-09-24 2011-08-31 Angioblast Systems Incorporated Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
CN101506355B (zh) 2004-09-24 2012-06-27 成血管细胞***公司 多能扩增间充质前体细胞子代（memp）及其应用
KR101617319B1 (ko) 2005-04-12 2016-05-02 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리
KR100679642B1 (ko) * 2005-11-16 2007-02-06 주식회사 알앤엘바이오 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
CN101370930A (zh) 2006-01-13 2009-02-18 奥西里斯治疗公司 表达TNF-α受体的间充质干细胞
EP1845154A1 (en) 2006-04-12 2007-10-17 RNL Bio Co., Ltd. Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same
DK2046349T3 (en) 2006-07-12 2015-12-21 Mesoblast Inc TREATMENT OF EXCESSIVE NEOVASCULARIZATION
MY165114A (en) 2006-09-01 2018-02-28 Stempeutics Res Private Limited Self-renewing master adult pluripotent stem cells
WO2008097828A2 (en) 2007-02-02 2008-08-14 St. Jude Children's Research Hospital Method for isolating mesenchymal stromal cells
WO2008129563A2 (en) 2007-04-23 2008-10-30 Stempeutics Research Private Limited, Human mesenchymal stem cells and preparation thereof
WO2008148105A1 (en) 2007-05-25 2008-12-04 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
EP2014294A1 (en) 2007-07-13 2009-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of CD200 as a mesenchymal stem cells marker
WO2009044943A1 (en) 2007-10-01 2009-04-09 Seoul National University Industry Foundation Various human dental stem cells having a mineralization ability and the method for culturing them
US8455251B2 (en) 2007-11-09 2013-06-04 Rnl Bio Co., Ltd. Method for isolating and culturing adult stem cells derived from human amniotic epithelium
EP2247285B1 (en) * 2007-11-30 2014-06-11 RNL Bio Co., Ltd. Cellular therapeutic agent for incontinence of urine comprising stem cells originated from decidua
EP2297305A4 (en) 2008-05-15 2013-03-13 Univ Miami ISOLATION OF STEM CELL PRECURSORS AND EXPANSION UNDER NON-ADHESION CONDITIONS
CA2729303A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
JP2011529706A (ja) 2008-08-04 2011-12-15 アローキュア インコーポレイテッド 間充織間質細胞集団、ならびにそれを単離および使用する方法
CN106995797B (zh) 2008-08-18 2021-04-30 中胚有限公司 单克隆抗体stro-4
JP5793724B2 (ja) 2008-08-22 2015-10-14 公益財団法人ヒューマンサイエンス振興財団 脳梗塞治療材
EP2334785B2 (en) 2008-09-16 2019-08-14 Mayo Foundation For Medical Education And Research Compositions containing platelet contents
EP2186883A1 (en) 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
CN104546912B (zh) 2008-11-20 2019-11-08 中胚有限公司 用于治疗胰功能异常的方法
WO2010126194A1 (ko) 2009-04-28 2010-11-04 (주) 안트로젠 누공 치료를 위한 자가 및 동종의 지방 유래 스트로마 줄기세포 조성물
US20110117064A1 (en) 2009-10-13 2011-05-19 Christof Westenfelder Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
ES2358146B1 (es) 2009-10-22 2012-03-23 Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla Uso de células mesenquimales nestina positivas para el mantenimiento de la hematopoyesis.
US20120269779A1 (en) 2009-10-30 2012-10-25 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
CN102048756B (zh) 2009-11-04 2014-02-19 中国医学科学院基础医学研究所 人脂肪来源的间充质干细胞在肾脏、眼底疾病中的用途
US8703487B2 (en) 2009-12-01 2014-04-22 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
EP2506867B1 (en) * 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
KR101871472B1 (ko) 2010-07-02 2018-06-27 메소블라스트, 아이엔씨. 이식편대숙주 질환의 치료 방법
JP6061345B2 (ja) 2010-08-27 2017-01-18 ユニヴァーシティ・オヴ・マイアミ 心臓修復のための骨髄由来ｃｄ２７１前駆細胞
EP3679939A1 (en) 2010-10-08 2020-07-15 Mesoblast International Sàrl Enhanced msc preparations
ES2384790B1 (es) 2010-12-10 2013-05-20 Instituto De Salud Carlos Iii Células madre mesenquimales aisladas a partir de sangre periférica.
US20120288480A1 (en) 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
CN102078644A (zh) * 2011-03-08 2011-06-01 吉林大学 一种简便高效的自体富血小板血浆提取装置及提取方法
US9388385B2 (en) 2011-05-19 2016-07-12 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
CN112891374A (zh) 2011-06-03 2021-06-04 麦瑟布莱斯特公司 治疗中风的影响的方法
JP6184942B2 (ja) 2011-06-03 2017-08-23 メゾブラスト，インコーポレーテッド 神経疾患を治療するまたは予防する方法
CN103826647A (zh) 2011-07-04 2014-05-28 麦瑟布莱斯特公司 治疗或预防风湿性疾病的方法
CN103857401B (zh) 2011-09-09 2018-06-05 麦瑟布莱斯特公司 增加成骨细胞功能的方法
EP2814951B1 (en) * 2012-02-13 2019-04-03 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
WO2013151725A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
US20130273011A1 (en) 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome

Also Published As

Publication number Publication date
AU2012279995C1 (en) 2019-10-24
EA029577B1 (ru) 2018-04-30
WO2013005053A2 (en) 2013-01-10
HUE039236T2 (hu) 2018-12-28
CA2840307A1 (en) 2013-01-10
AU2012279995B2 (en) 2017-03-30
US20200048613A1 (en) 2020-02-13
PL2729562T3 (pl) 2018-10-31
IL230071B (en) 2019-02-28
AU2012279995A1 (en) 2014-01-23
HRP20181152T1 (hr) 2018-09-21
WO2013005053A3 (en) 2013-06-13
CA2840307C (en) 2021-10-19
NZ620283A (en) 2016-06-24
PT2729562T (pt) 2018-07-18
CN107746830A (zh) 2018-03-02
SG10201605518XA (en) 2016-08-30
EP2729562A2 (en) 2014-05-14
IL264455A (en) 2019-02-28
EP2729562B1 (en) 2018-04-18
AU2017204559A1 (en) 2017-07-20
US20150071886A1 (en) 2015-03-12
LT2729562T (lt) 2018-07-25
US10829739B2 (en) 2020-11-10
JP6607675B2 (ja) 2019-11-20
DK2729562T3 (en) 2018-07-23
US11873513B2 (en) 2024-01-16
US10472609B2 (en) 2019-11-12
JP2017225451A (ja) 2017-12-28
JP2014520523A (ja) 2014-08-25
CN104508124A (zh) 2015-04-08
CN104508124B (zh) 2017-11-17
MY185016A (en) 2021-04-30
US20210032600A1 (en) 2021-02-04
EA201391773A1 (ru) 2014-11-28
ES2675693T3 (es) 2018-07-11

Similar Documents

Publication Publication Date Title
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
CY1120219T1 (el) Ανταγωνιστες της il17c για τη θεραπευτικη αντιμετωπιση φλεγμονωδων διαταραχων
UY34254A (es) Proteínas y péptidos modificados.
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
UY34822A (es) Composiciones y métodos para silenciar la expresión genética
UY34763A (es) Inhibidores de la agregación plaquetaria
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
UY4235Q (es) Configuración aplicada en zapato
UY34683A (es) Esteviol glucosiltransferasas y genes que las codifican
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
RS53893B1 (en) USE OF BIOTIN FOR MULTIPLE SCLEROSIS TREATMENT
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
TWD158887S (zh) 粉餅盒
UY4281Q (es) Juguera
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
UY34603A (es) Anticuerpos anti-asic-1 y usos de los mismos
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)